• Home
  • About Us
  • Contact
  • Subscribe
  • Your Account
  • Login
No Result
View All Result
Monday, May 29, 2023
Alternatives Watch
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
No Result
View All Result
Alternatives Watch
No Result
View All Result

OrbiMed attracts $3.5bn across three healthcare funds

Susan BarretobySusan Barreto
March 2, 2021
in Manager News, Manager News, Private Credit, Private Equity
OrbiMed attracts $3.5bn across three healthcare funds

By RF._.studio/Pexels

ShareTweetShareSendSend

OrbiMed saw $3.5 billion in fresh investor commitments in its latest private investment fund offerings from a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.

Three fund closures were reported by officials this week with OrbiMed Private Investments VIII attracting $1.5 billion in capital, $800 million for OrbiMed Asia Partners IV and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.

As observed within the Alternatives Watch healthcare beat, OrbiMed has been an active investor on many fronts in recent months. Where appropriate, the firm invests across multiple funds bringing potential investment amounts to upwards of $250 million per portfolio company. Some of this investment work of course has been focused in Asia, where the firm was among the Series C investors in Gracell Biotechnologies last year.

With a focus on China and India, OrbiMed Asia Partners IV allocates in venture capital deals through growth stage across biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services. The investments range from $10 million to $100 million with the fund’s holdings spanning across 20 portfolio companies.

OrbiMed Private Investments VIII, meanwhile, invests in venture capital opportunities in North America and Europe with a focus on biotechnology, medical device and diagnostics companies in targeted investments ranging from $10 million to $100 million across 40 portfolio companies.

Lastly, OrbiMed Royalty & Credit Opportunities III puts capital to work globally through structured credit and royalty monetization financing solutions aimed at healthcare companies and institutions. The investment range is from $10 million to $150 million per opportunity.

The new fund commitments bring the firm’s AUM to $18 billion across public equity, private equity and credit/royalty strategies. OrbiMed seeks to partner with healthcare companies across their life cycle from start-up seed capital through to growth equity and non-dilutive debt capital.

Tags: BiotechLife SciencesOrbiMed
ShareTweetShareSendSend
Previous Post

CORE closes second fund at $465m

Next Post

Software-focused JMI hits hard cap at $1.7bn

Related Posts

People moves for week of May 26
Hedge Funds

People moves for week of May 26

Godspeed raises $250m for second investment program
Private Equity

Godspeed raises $250m for second investment program

CPP allocates nearly $6bn to 2023 private equity vintage
Pensions

CPP allocates nearly $6bn to 2023 private equity vintage

New Jersey hires head of private equity
Investor News

New Jersey hires head of private equity

A balancing act: U.S. managers eye a new structure in a new jurisdiction
Features

A balancing act: U.S. managers eye a new structure in a new jurisdiction

Next Post
Software-focused JMI hits hard cap at $1.7bn

Software-focused JMI hits hard cap at $1.7bn

Log In/Out

Lost your password?

Search the AW Archives

No Result
View All Result

Recent News

People moves for week of May 26

People moves for week of May 26

Chatham sounds warning on RYAM debt maturities

Chatham sounds warning on RYAM debt maturities

Godspeed raises $250m for second investment program

Godspeed raises $250m for second investment program

CPP allocates nearly $6bn to 2023 private equity vintage

CPP allocates nearly $6bn to 2023 private equity vintage

Be an Alts Insider

Sign up for your FREE daily alts news briefing

Subscribe

Subscribe to AW
Alternatives Watch

© 2019-2022, All Rights Reserved  |  BMV Digital

Navigate Site

  • Investor News
  • Private Equity
  • Private Credit
  • Hedge Funds
  • Real Estate/Infrastructure
  • Subscribe
  • Your Membership
  • Terms of Service
  • Privacy Policy

Follow Us

No Result
View All Result
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe

© 2019-2022, All Rights Reserved  |  BMV Digital

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Be an alts insider

Start your days in the know with our free newsletter

No, I don't want to be an alts insider

Thank

You!

Follow us
on LinkedIn

Lost your password?

This Website Uses Cookies
We use cookies on our website to provide necessary functions. By clicking “Accept”, you consent to the use of all strictly necessary cookies.
Do not sell my personal information.
Cookie Settings Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Save & Accept
Powered by CookieYes Logo